How Pharmacies Should Use VRS Tools to Document DSCSA Compliance

Pharmacies and dispensers became subject to DSCSA enhanced drug distribution security requirements on November 27, 2024. As of that date, pharmacies must verify product identifiers, authenticate trading partners, and maintain electronic records of all transactions involving prescription drugs. The verification routing service (VRS) is the DSCSA infrastructure layer that routes verification requests between trading partners — and pharmacies must document their use of VRS tools to demonstrate compliance during inspections and audits.

Regulatory Background

The Drug Supply Chain Security Act (Public Law 113-54) established a phased implementation timeline for electronic track-and-trace requirements. The final phase, which took effect in November 2024, requires dispensers to:

• Verify product identifiers at the package level before dispensing (21 U.S.C. § 360eee-1(d)(1)(C))
• Respond to verification requests from authorized trading partners within 24 hours (21 U.S.C. § 360eee-1(d)(1)(D))
• Maintain electronic transaction records for six years (21 U.S.C. § 360eee-1(d)(1)(E))

VRS is not mandated by statute. However, FDA guidance documents and industry practice have established VRS as the de facto mechanism for routing verification requests in the U.S. pharmaceutical supply chain. Without a VRS connection, pharmacies cannot practically fulfill their obligation to respond to verification requests from wholesale distributors, repackagers, or other authorized trading partners.

What VRS Does in DSCSA Compliance

A verification routing service acts as an intermediary that connects disparate systems across the supply chain. When a trading partner initiates a verification request — for example, a wholesaler receiving returned product from a pharmacy — the VRS routes that request to the appropriate entity based on the product's serialized Global Trade Item Number (GTIN) and serial number.

For pharmacies, VRS enables two critical compliance activities:

Inbound verification: When a pharmacy receives product, it can query the VRS to verify that the product identifier matches the manufacturer's serialization data. This confirms product authenticity and detects potential diversions or counterfeits.

Outbound verification response: When a pharmacy returns product to a wholesaler or transfers product to another dispenser, the receiving party may initiate a verification request. The pharmacy must respond through the VRS within 24 hours, confirming or denying possession of that serialized unit at the time of the transaction.

Documentation Requirements

FDA inspection guidance for DSCSA compliance focuses on whether a pharmacy can demonstrate that it has systems and processes in place to fulfill its verification obligations. VRS documentation falls into three categories:

1. System configuration records: Documentation proving the pharmacy has an active VRS connection. This includes VRS provider contracts, system integration logs, and confirmation that the pharmacy's unique identifier (typically its DEA number) is registered in the VRS network.

2. Transaction-level verification records: Logs showing that the pharmacy successfully transmitted or received verification requests through the VRS. Each record should include the GTIN, serial number, lot number, expiration date, transaction date, and the identity of the requesting or responding party.

3. Exception handling records: Documentation of how the pharmacy responded when a verification request failed. DSCSA regulations require pharmacies to quarantine product and investigate discrepancies when verification results do not match expected data (21 U.S.C. § 360eee-1(d)(4)(A)).

State boards of pharmacy may impose additional recordkeeping requirements. For example, California Business and Professions Code § 4163.2 requires California pharmacies to maintain DSCSA records "in a readily retrievable manner" and to produce them within 24 hours of an inspection request.

What ColdChainCheck Data Shows About VRS Readiness

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain providers across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration — a baseline requirement for any entity handling prescription drugs subject to DSCSA. However, FDA registration does not capture VRS connectivity or serialization system implementation.

The average compliance score in the ColdChainCheck directory is 51/100. This score reflects verified licensure, accreditation, and regulatory standing — but does not yet include VRS participation as a scored dimension, because VRS provider data is not publicly available through a consolidated federal or state database. Only 63 entities hold NABP accreditation (formerly VAWD), which requires demonstrable compliance with DSCSA serialization and verification requirements as part of the accreditation audit process. This represents less than 5% of tracked entities.

The compliance score distribution shows 919 entities in the "Fair" tier (40-59 points). These entities typically hold active state licenses and FDA registration, but lack NABP accreditation or have gaps in publicly verifiable compliance signals. For pharmacies conducting trading partner due diligence, this distribution suggests that most wholesale distributors have baseline regulatory standing, but additional verification is needed to confirm VRS connectivity and DSCSA systems readiness.

Practical Steps for Pharmacies Using ColdChainCheck

• Cross-reference VRS connectivity against regulatory standing: Before onboarding a new wholesale distributor or 3PL, check the entity's compliance score in the ColdChainCheck directory. A score below 40 may indicate expired licenses or enforcement actions that signal broader compliance gaps. Request written confirmation of VRS participation and ask which VRS provider(s) the entity uses.

• Prioritize NABP-accredited trading partners: The 63 NABP-accredited entities in the directory have undergone third-party audits confirming DSCSA systems compliance, including serialization and verification capabilities. Filter the directory by NABP accreditation status when qualifying new trading partners for high-value or controlled substance transactions.

• Monitor enforcement actions that may signal VRS gaps: ColdChainCheck tracks 73 entities with FDA recalls on record. While not all recalls relate to DSCSA violations, entities with recent enforcement actions may have weaker systems for verification and traceability. Review the enforcement history before finalizing trading partner agreements.

• Document due diligence for audit readiness: During state board or FDA inspections, pharmacies must demonstrate that they verified their trading partners' authorization under DSCSA (21 U.S.C. § 360eee-1(d)(4)(B)). Use ColdChainCheck compliance score reports as one component of a documented trading partner qualification process. For methodology and related DSCSA guidance, see the ColdChainCheck compliance guides.

Disclaimer: This article is provided for informational purposes only and does not constitute legal or regulatory advice. Pharmacies should consult qualified legal counsel and verify all compliance requirements with the relevant federal and state authorities.

Update: DSCSA VRS Implementation: Wholesale Distributor Compliance Guide

March 17, 2026

How Wholesale Distributors Are Supporting Pharmacy DSCSA Compliance Through VRS Tools

Wholesale distributors are implementing verification routing services (VRS) to help downstream pharmacies meet DSCSA serialization requirements before the November 2027 unit-level traceability deadline. Cencora, the largest pharmaceutical wholesaler in the United States, has publicly outlined its approach to pharmacy VRS implementation—clarifying a compliance pathway that affects 1,275 wholesale drug distributors and thousands of retail and specialty pharmacies.

Regulatory Context: DSCSA Enhanced Drug Distribution Security Requirements

The Drug Supply Chain Security Act (DSCSA), enacted under Title II of the Drug Quality and Security Act of 2013, establishes an interoperable, electronic system for identifying and tracing prescription drugs distributed in the United States. Under 21 U.S.C. § 360eee-1, wholesale distributors and dispensers must be able to verify the legitimacy of prescription drugs and respond to suspect or illegitimate product notifications.

The November 27, 2027 deadline marks the transition to enhanced drug distribution security requirements under 21 U.S.C. § 360eee-1(g). After this date, all trading partners must exchange product tracing information at the package level (serialized data) rather than lot-level aggregated data. Dispensers—including pharmacies—must be able to verify product identifiers, conduct investigations, and quarantine suspect products using serialized data systems.

Verification routing services are the technical infrastructure that enables this downstream compliance. A VRS acts as an intermediary system that receives verification requests from dispensers, routes those requests to the appropriate product data holder (typically the manufacturer or its solution provider), and returns authentication responses. The FDA's draft guidance on DSCSA implementation (published September 2023) explicitly recognizes VRS as an acceptable method for dispensers to verify product identifiers under 21 CFR 1271.440(b)(4)(ii).

Wholesale Distributor Role in VRS Implementation

Wholesale distributors occupy a structural position between manufacturers and dispensers in the pharmaceutical supply chain. This position creates both compliance obligations and service opportunities. Under DSCSA, distributors must provide transaction information (TI), transaction history (TH), and transaction statements (TS) to downstream trading partners. As of November 2027, this TI/TH/TS must include serialized product identifiers.

Cencora's VRS implementation model addresses a critical pharmacy pain point: independent and small-chain pharmacies often lack the capital budget and IT infrastructure to implement native DSCSA verification systems. By offering VRS access through existing wholesale distributor ordering platforms, Cencora enables pharmacies to meet verification requirements without purchasing standalone EPCIS (Electronic Product Code Information Services) systems or joining manufacturer-specific verification networks.

The operational mechanics work as follows: when a pharmacy receives a product shipment, it scans the 2D barcode containing the serialized National Drug Code (NDC), serial number, lot number, and expiration date. The VRS system submits this data to the product's authoritative source (typically the manufacturer's serialization database), which confirms whether the serial number is valid and matches the expected transaction history. The pharmacy receives a pass/fail response within seconds. This verification must occur before product dispensing for suspect product investigations or saleable returns verification.

Compliance Implications for Wholesale Drug Distributors

Wholesale distributors face three distinct compliance considerations related to VRS implementation:

Direct regulatory obligation: Distributors must be able to verify products they receive from upstream trading partners and must respond to verification requests from downstream trading partners. This is a statutory requirement under 21 U.S.C. § 360eee-1(c)(4)(B).

Operational integration: Distributors that offer VRS services to pharmacy customers must integrate those systems with existing transaction data exchanges. Pharmacies need serialized TI/TH/TS for every product they receive, and those data sets must reconcile with VRS verification responses. Mismatches between transaction data and verification responses trigger suspect product investigations.

Trading partner qualification: The DSCSA requires distributors to verify that their trading partners are authorized. Offering VRS services does not eliminate this obligation. Distributors must still confirm that downstream pharmacies hold active state pharmacy licenses and are authorized to receive prescription drugs in their jurisdiction.

Wholesale distributors that do not implement VRS offerings are not non-compliant—VRS is one pathway, not the only pathway. However, distributors must still provide serialized transaction data to all downstream customers and must respond to verification requests. Pharmacies that cannot verify products through their wholesale distributor will need to establish direct manufacturer connections or purchase third-party verification solutions, which may affect distributor-pharmacy relationships and contract terms.

What ColdChainCheck Data Shows About Wholesale Distributor DSCSA Readiness

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. The average compliance score of 51/100 places the industry in the "Fair" tier—indicating that while most entities maintain basic licensure and FDA registration, fewer demonstrate comprehensive compliance signals across all tracked dimensions.

DSCSA serialization readiness is not directly captured in ColdChainCheck's scoring methodology (the score reflects state licensure, FDA registration, NABP accreditation, recall history, enforcement actions, and operating duration). However, the score distribution provides context for assessing industry implementation capacity:

• 28 entities (2.2%) score "Excellent" (81-100 points): These distributors maintain verified state licenses in multiple jurisdictions, hold NABP accreditation, demonstrate clean regulatory records, and operate established businesses. These are the entities most likely to have already implemented VRS infrastructure or have capital budgets allocated for November 2027 compliance.

• 281 entities (22%) score "Good" (61-80 points): This tier represents distributors with strong state licensure coverage and FDA registration but limited NABP accreditation (only 63 entities industry-wide hold NABP accreditation). These distributors likely have compliance programs in place but may be implementing VRS services for the first time.

• 919 entities (72%) score "Fair" (41-60 points): The majority of tracked distributors fall into this range. Fair-tier entities typically hold licenses in their primary operating states and maintain FDA registration, but lack multi-state coverage or NABP verification. For smaller regional distributors in this tier, VRS implementation may represent a significant IT investment relative to operating scale.

The 63 NABP-accredited entities in ColdChainCheck's directory warrant specific attention. NABP's Verified-Accredited Wholesale Distributors (VAWD) program requires applicants to demonstrate compliance with DSCSA transaction documentation requirements as part of the accreditation criteria. NABP-accredited distributors are disproportionately likely to have serialization infrastructure already deployed, making them lower-risk trading partners for pharmacies seeking VRS support.

Practical Steps for Compliance Officers

QA managers and regulatory affairs teams evaluating wholesale distributor VRS capabilities should take the following actions:

• Cross-reference trading partners in the ColdChainCheck directory to verify current state licensure and FDA registration status. Entities offering VRS services must themselves be compliant with DSCSA enhanced requirements—a distributor cannot provide verification services if it lacks the technical capability to exchange serialized transaction data.

• Prioritize NABP-accredited distributors for VRS partnerships. The 63 entities with NABP accreditation represent the subset of wholesale distributors that have submitted to third-party audits confirming DSCSA compliance infrastructure. Filter the directory by NABP status to identify these entities by jurisdiction.

• Monitor recall and enforcement histories for entities claiming VRS readiness. The 73 entities in ColdChainCheck's directory with FDA recalls on record should receive enhanced due diligence. A history of product quality issues or documentation failures may indicate systemic compliance gaps that could affect serialization data integrity.

• Document verification vendor qualifications as part of trading partner agreements. VRS services create a three-party relationship: distributor, pharmacy, and manufacturer verification network. Compliance teams should request documentation showing the distributor's connection to manufacturer EPCIS repositories and verification response time SLAs.

ColdChainCheck tracks state licensure changes, FDA enforcement actions, and NABP accreditation status updates as compliance signals. For ongoing DSCSA implementation guidance, see the regulatory guides section for detailed coverage of serialization requirements, verification system standards, and trading partner qualification processes.

Disclaimer: This content is for informational purposes only and does not constitute legal or regulatory advice. Wholesale distributors and pharmacies should consult qualified legal counsel and verify all compliance requirements with the FDA and relevant state boards of pharmacy.